CoChat

Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies

Open access
Shi, Zhen-Duo, Pang, Kun, Wu, Zhuo-Xun, Dong, Yang, Hao, Lin, Qin, Jia-Xin, Wang, Wei, Chen, Zhe-Sheng, Han, Cong-Hui · 2023 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 374 of the 374 references it cites were found in a registry or an index.

Abstract

Despite the success of targeted therapies in cancer treatment, therapy-induced resistance remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via phenotypic switching driven by intrinsic or induced cell plasticity. Several reversible mechanisms have been proposed to circumvent tumor cell plasticity, including epigenetic modifications, regulation of transcription factors, activation or suppression of key signaling pathways, as well as modification of the tumor environment. Epithelial-to-mesenchymal transition, tumor cell and cancer stem cell formation also serve as roads towards tumor cell plasticity. Corresponding treatment strategies have recently been developed that either target plasticity-related mechanisms or employ combination treatments. In this review, we delineate the formation of tumor cell plasticity and its manipulation of tumor evasion from targeted therapy. We discuss the non-genetic mechanisms of targeted drug-induced tumor cell plasticity in various types of tumors and provide insights into the contribution of tumor cell plasticity to acquired drug resistance. New therapeutic strategies such as inhibition or reversal of tumor cell plasticity are also presented. We also discuss the multitude of clinical trials that are ongoing worldwide with the intention of improving clinical outcomes. These advances provide a direction for developing novel therapeutic strategies and combination therapy regimens that target tumor cell plasticity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01383-x

Cites

374 of 374 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Changes in acquired therapy resistance induced by treatment initiation and discontinuation, with different scenarios employed to interpret the development of the therapy-resistant phenotype. According to the Darwinian selection model, drug-tolerant persistors (DTPs) that originated from the primary tumor tissue are selected and enriched by treatments. The Lamarckian induction model regards the acquired drug-indifferent phenotype as the result of tumor cell adaptation to treatments that leads to formation of induced DTPs. The coexisting model suggests that formation of both primary and induced DTPs occur and together contribute to the acquired therapy resistance
Fig. 1 Changes in acquired therapy resistance induced by treatment initiation and discontinuation, with different scenarios employed to interpret the development of the therapy-resistant phenotype. According to the Darwinian selection model, drug-tolerant persistors (DTPs) that originated from the primary tumor tissue are selected and enriched by treatments. The Lamarckian induction model regards the acquired drug-indifferent phenotype as the result of tumor cell adaptation to treatments that leads to formation of induced DTPs. The coexisting model suggests that formation of both primary and induced DTPs occur and together contribute to the acquired therapy resistanceCC BY · PubMed Central
Fig. 2 Therapeutic resistance involvement in epigenetic modifications and EMT/MET. a Schematic representation of therapy-induced drug resistance through chemical epigenetic modifications. Four core histone proteins (H2A, H2B, H3, and H4) can be diversely modified by multiple enzymes that result in methylation, acetylation, phosphorylation, or ubiquitylation. DNA can be methylated at the 5-carbon of the cytosine base to form 5-methylcytosine (5-mC), which can be further oxidized to form 5-hydroxymethyl cytosine (5-hmC). Enzymes involved in the epigenetic modifications of either histone or DNA can be utilized as potential future therapeutic targets against tumor cell plasticity. K, Lysine; S, Serine; R, Arginine; T, Threonine; me, methylation; ac, acetylation; ub, ubiquitination; P, phosphorylation; HAT, histone acetyltransferase; HMT, histone methyltransferase; HDAC, histone deacetylase; HDM, histone demethylase; TRIM, tripartite mortif; MSK1, mitogen- and stress-activated protein kinase 1; DNMT, DNA methyltransferase; TET, ten-eleven translocation enzymes. b Primary tumor cells undergo EMT and MET to achieve metastasis. Primary tumor cells undergo EMT by losing epithelial traits and acquiring mesenchymal characteristics, which enables tumor cells to migrate and invade into blood or lymphatic vessels. In circulation, tumor cells exhibit a “partial EMT” within the epithelial-mesenchymal spectrum. During colonization, migratory tumor cells with mesenchymal traits undergo MET to restore epithelial characteristics and proliferate to form a secondary tumor. Therapeutic resistance and invasiveness are higher in mesenchymal states, whereas a hybrid state of epithelial and mesenchymal indicates the highest level of stemness and capacity of self-adaptation. The process of EMT/MET is regulated by crosstalk among genomic factors, MET-TFs, and multiple signaling pathways. EM, epithelial-mesenchymal transition, MET mesenchymal-epithelial transition, TF transcription factor, miR microRNA
Fig. 2 Therapeutic resistance involvement in epigenetic modifications and EMT/MET. a Schematic representation of therapy-induced drug resistance through chemical epigenetic modifications. Four core histone proteins (H2A, H2B, H3, and H4) can be diversely modified by multiple enzymes that result in methylation, acetylation, phosphorylation, or ubiquitylation. DNA can be methylated at the 5-carbon of the cytosine base to form 5-methylcytosine (5-mC), which can be further oxidized to form 5-hydroxymethyl cytosine (5-hmC). Enzymes involved in the epigenetic modifications of either histone or DNA can be utilized as potential future therapeutic targets against tumor cell plasticity. K, Lysine; S, Serine; R, Arginine; T, Threonine; me, methylation; ac, acetylation; ub, ubiquitination; P, phosphorylation; HAT, histone acetyltransferase; HMT, histone methyltransferase; HDAC, histone deacetylase; HDM, histone demethylase; TRIM, tripartite mortif; MSK1, mitogen- and stress-activated protein kinase 1; DNMT, DNA methyltransferase; TET, ten-eleven translocation enzymes. b Primary tumor cells undergo EMT and MET to achieve metastasis. Primary tumor cells undergo EMT by losing epithelial traits and acquiring mesenchymal characteristics, which enables tumor cells to migrate and invade into blood or lymphatic vessels. In circulation, tumor cells exhibit a “partial EMT” within the epithelial-mesenchymal spectrum. During colonization, migratory tumor cells with mesenchymal traits undergo MET to restore epithelial characteristics and proliferate to form a secondary tumor. Therapeutic resistance and invasiveness are higher in mesenchymal states, whereas a hybrid state of epithelial and mesenchymal indicates the highest level of stemness and capacity of self-adaptation. The process of EMT/MET is regulated by crosstalk among genomic factors, MET-TFs, and multiple signaling pathways. EM, epithelial-mesenchymal transition, MET mesenchymal-epithelial transition, TF transcription factor, miR microRNACC BY · PubMed Central
Fig. 3 Mechanisms driving tumor cell plasticity and drug resistance. Both tumor microenvironment factors and EMT-related signaling pathways regulate the EMT process. The activation of EMT facilitates the dedifferentiation of non-cancer stem cells (CSCs) to CSC, which contributies to tumor heterogeneity
Fig. 3 Mechanisms driving tumor cell plasticity and drug resistance. Both tumor microenvironment factors and EMT-related signaling pathways regulate the EMT process. The activation of EMT facilitates the dedifferentiation of non-cancer stem cells (CSCs) to CSC, which contributies to tumor heterogeneityCC BY · PubMed Central
Fig. 4 Therapeutic strategies targeting tumor cell plasticity. Three main strategies can be used in combination treatment against tumor cell plasticity: 1) prevent tumor cell plasticity; 2) reverse the phenotypic switching; and 3) direct therapy to target the induced therapy-resistant tumor cells
Fig. 4 Therapeutic strategies targeting tumor cell plasticity. Three main strategies can be used in combination treatment against tumor cell plasticity: 1) prevent tumor cell plasticity; 2) reverse the phenotypic switching; and 3) direct therapy to target the induced therapy-resistant tumor cellsCC BY · PubMed Central
Fig. 5 Combination treatments for overcoming the tumor cell plasticity induced-therapy resistance. Tumor cells evade targeted treatments by interacting with TME and via EMT programs. Inflammation, hypoxia, and immunosuppressive TME contribute to therapy evasion, and such induced-resistance could be inhibited by a combination treatment including anti-inflammation and anti-hypoxic drugs and immunosuppressive ICB regimens. EMT-modulating agents, on the other hand, could also deal with plasticity induced-therapy resistance as a combination treatment and lead to tumor cell death. TME tumor microenvironment, EMT epithelial-to-mesenchymal transition, ICB immune checkpoint blockade, Rg3 ginseng-extracted 20(R)-Ginsenoside
Fig. 5 Combination treatments for overcoming the tumor cell plasticity induced-therapy resistance. Tumor cells evade targeted treatments by interacting with TME and via EMT programs. Inflammation, hypoxia, and immunosuppressive TME contribute to therapy evasion, and such induced-resistance could be inhibited by a combination treatment including anti-inflammation and anti-hypoxic drugs and immunosuppressive ICB regimens. EMT-modulating agents, on the other hand, could also deal with plasticity induced-therapy resistance as a combination treatment and lead to tumor cell death. TME tumor microenvironment, EMT epithelial-to-mesenchymal transition, ICB immune checkpoint blockade, Rg3 ginseng-extracted 20(R)-GinsenosideCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 374 references

Research works printed but not linked: 1

  1. Yingling, J. M. et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-beta receptor type I inhibitor. Oncotarget 9, 6659–6677 (2018). · DOI · Paper page

Cited by

See all 287

Metadata

Authors
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H.
Affiliations
  • Xuzhou Medical College (CN)
  • St. John's University (US)
  • Southeast University (CN)
Corresponding author
Chen, Zhe-Sheng
Venue
Signal Transduction and Targeted Therapy
Published
2023-03-11
Volume
8
Issue
1
Pages
113-113
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4323924126
Cited by
256
References
374
Citations by year
2026: 85 · 2025: 92 · 2024: 59 · 2023: 20
FWCI
8.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81774089, KC19075, BE2020758, 12271467, 82004110, BE2019637)
  • Government of Jiangsu Province
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
tumor plasticity, targeted therapy resistance, acquired drug resistance, phenotypic switching, epithelial-mesenchymal transition, cancer stem cells, epigenetic modifications, transcription factors, tumor microenvironment, combination therapy
MeSH terms
Cell Plasticity, Humans, Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. https://app.cochat.ai/papers/10.1038/s41392-023-01383-x
The paper
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023). Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01383-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.